Instil Bio, Inc.

$18.21 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Instil Bio, Inc.

Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. It is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. It is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its lead CoStAR-TIL product candidate. ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (FOLR1), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer.

Stock Analysis

last close $18.21
1-mo return -15.3%
3-mo return -6.1%
avg daily vol. 243.33T
52-week high 29.49
52-week low 14.42
market cap. $2.3B
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $0M
inst own. 55%
baraka

Subscribe now for daily local and international financial news

Subscribe